Lensar (LNSR) Long-Term Investments (2023 - 2024)

Lensar's (LNSR) quarterly Long-Term Investments came in at $494000.0 in Q3 2024, down 59.97% on a QoQ basis from $1.2 million in Q2 2024.

Lensar (LNSR) Long-Term Investments (2023 - 2024) Analysis & Trends

Lensar (LNSR) has 2 years of Long-Term Investments data on file, last reported at $494000.0 in Q3 2024.

On a quarterly basis, Long-Term Investments changed N/A year-over-year to $494000.0 in Q3 2024; TTM through Sep 2024 was $494000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $492000.0, changed N/A from the prior year.
Long-Term Investments for Q3 2024 stood at $494000.0, down from $1.2 million in the prior quarter.
Over the last five years, Long-Term Investments for LNSR reached as high as $1.2 million in Q1 2024 and fell as low as $492000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	1.09 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	-
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	-
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	-
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	285.60 Mn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	166.25 Mn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	-
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	121.00 Mn
10	Lensar	70.05 Mn	72.73 Mn	6.38 Mn	-

Download Data